Healthcare Industry News: Baxter International
News Release - May 6, 2011
Cytori Announces Clyde W. Shores as Executive Vice President of Marketing & SalesSAN DIEGO, CA--(Healthcare Sales & Marketing Network) - Cytori Therapeutics (NASDAQ:CYTX ) has appointed Clyde W. Shores as Executive Vice President of Marketing & Sales where he will lead the Company's strategic marketing initiatives for all product lines around the world.
Specifically, Mr. Shores will spearhead Cytori's preparations for the formal launch of the next-generation Celution® One System for hospital based sales. Mr. Shores will also oversee strategy and initiatives to drive adoption and use of Cytori's existing products, including the Celution® 800 and PureGraft™ Systems as well as StemSource® cell and tissue banking, and will lay the foundation for new regional and indication-based claims for our existing products in both the EU and the US.
"Cytori has undergone an extensive search for the ideal leader of its marketing team," said Marc H. Hedrick, President of Cytori Therapeutics. "With his background in cell therapy, medical devices and pharmaceuticals, Clyde is uniquely qualified to drive our marketing efforts as we continue to lead the way in regenerative medicine. His entrepreneurial spirit, combined with broad experience with high growth products and industries, will allow him to integrate seamlessly with the existing culture at Cytori and add tremendous value to our marketing and sales teams."
Mr. Shores has 27 years experience in medical marketing and sales and has been involved in the launch and marketing of multiple innovative medical products such as Amgen's revolutionary Neupogen®. Most recently, Mr. Shores served as Vice President of Global Marketing for Baxter International's Renal Business. Prior to Baxter, Mr. Shores worked for Abbott Laboratories, Amgen, Prometheus Laboratories and deCODE Genetics.
During his 9 years at Amgen and tenure with other companies, he developed a fundamental understanding of the potential for stem cell pharmaceuticals and devices, the commercialization of innovative therapeutics and the marketing and sales capabilities required to achieve significant revenue growth in global markets.
Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. Our PureGraft™ products are available in North America and Europe for fat grafting procedures. www.cytori.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings Form 10-K and 10Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Source: Cytori Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.